Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
August 28, 2002 at 12:47 PM EDT

Quidel Names Mark A. Pulido to Its Board of Directors; Adds Impressive Healthcare Channel Management and Fortune 50 Expertise

SAN DIEGO, Aug 28, 2002 /PRNewsire-FirstCall via Comtex/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced the appointment of Mark A. Pulido to the company's board of directors. Pulido brings Fortune 50 executive leadership experience and significant technology and healthcare channel management knowledge to the Quidel board. Pulido fills a board vacancy created by the retirement from the board of Richard C.E. Morgan earlier this year, bringing the total number of Quidel directors to seven.

Prior to his retirement in June, Pulido, 50, served as the chairman of the board of BenefitPoint, Inc., where he also served as the company's president and chief executive officer. During his tenure, Pulido is credited with creating the industry standard for online employee benefits infrastructure companies in the $600 billion employee benefits industry.

Previously, Pulido was president and chief executive officer of McKesson Corporation, a $50 billion provider of supply, information and care management products and services designed to reduce costs and improve quality across healthcare. He also served as the president and chief executive officer of Sandoz Pharmaceuticals Corporation (now Novartis) and Redline Healthcare Corporation.

Pulido has served on the board of directors of the Charles Schwab Corporation and Imation Corporation. He earned his B.S. in Pharmacy from the University of Arizona, College of Pharmacy and his M.S. in Pharmacy Administration at the University of Minnesota, College of Pharmacy.

"We are fortunate to have an individual of Mark's stature join our board," said S. Wayne Kay, president and chief executive officer of Quidel. "His knowledge of the operational, distribution and strategic aspects of the healthcare industry will be invaluable to Quidel as we continue on our path of technological and operational excellence."

Commenting on his board appointment, Pulido said, "Quidel has shown industry leadership with its growing portfolio of innovative products that make an impact on the way medical conditions and illnesses are detected and managed at the point of care. I am pleased to be a part of the effort dedicated to serving this important market, and I am enthusiastic about the future prospects of the company."

According to Andre de Bruin, Quidel's chairman, "During an impressive 25-year career, Mark has achieved a position of prominence in the healthcare industry. He is a seasoned executive with an excellent record of success in growing companies and in leveraging opportunities presented by an ever- changing industry. We are delighted he has accepted our offer to join the Quidel board of directors."

About Quidel

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point- of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com .

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the FDA and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" and in other sections of our Form 10-K for year ended December 31, 2001, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this presentation. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.

CONTACT:
media, Bea Evangelista of Euro RSCG Middleberg,
+1-212-699-2503, bea.evangelista@eurorscg.com, for Quidel Corporation; or
investors, Ina McGuinness of Lippert